May 24, 2022
InSysBio announces the creation of a new legal entity INSYSBIO CY Ltd. InSysBio continues the development of its QSP services and QSP tools infrastructure and contributing its experience to global research.
Oleg Demin, CEO of InSysBio, comments on the significance and goals of this step, "I am pleased to share that we have created a new legal entity, INSYSBIO CY Ltd, and are currently in the process of relocating InSysBio employees to Cyprus. Moving is not an easy step for anyone who decides to start their life and career in a new country. But I am sure that soon Cyprus will become one of the countries distinguished on the “QSP community map” together with USA, UK, Russia, India and many others. We will do all our best to achieve this goal. For this purpose we will proceed with development of QSP software infrastructure including heta family and QSP databases and, of course, we continue our theoretical and applied research focused on delivering "best of class" QSP and PBPK/RO models to our customers and collaborators. I hope that QSP community will encourage us in our efforts and, in our turn, InSysBio will continue development of "QSP modeling" theory and contributing it into the drug development practice".
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | December 2019 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
| ||||||
|
2
|
3
1.
03 Dec 2019 15:35
InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting
QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.
|
4
|
5
|
6
|
7
|
8
|
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
30
|
31
| |||||
Thank you for your message! We will get back to you shortly.
